胰腺癌术后吉西他滨辅助治疗的化疗耐药特征及预后相关性分析  

Analysis of Chemotherapy Resistance Characteristics and Prognostic Correlation of Gemcitabine Adjuvant Chemotherapy after Pancreatic Cancer Surgery

作　　者：周晓 陈康 马常欢 杨波 杨晏 ZHOU Xiao;CHEN Kang;MA Changhuan;YANG Bo;YANG Yan(Department of Hepatobiliary Pancreatic Surgery,Changzhou Maternal and Child Health Hospital(Zhonglou Branch of Changzhou First Hospital),Changzhou,Jiangsu 213000,China)

机构地区：[1]常州妇幼保健院(常州一院钟楼分院)肝胆胰外科,江苏常州213000

出　　处：《转化医学杂志》2024年第11期1974-1977,1981,共5页Translational Medicine Journal

基　　金：常州市妇幼保健院科研基金(YJ202415)。

摘　　要：目的探讨胰腺癌术后接受吉西他滨辅助治疗患者化疗耐药与临床特征的关系,以及对患者预后的影响。方法选取2022年1月至2023年12月在常州市妇幼保健院确诊为胰腺癌并接受治疗的100例患者为研究对象,回顾性分析患者化疗耐药与临床特征及预后的相关性。结果肿瘤大小可能为影响化疗耐药性的关键因素(HR=3.75,P<0.0001)。化疗耐药组患者的总生存期较差(HR=15.82,P<0.0001);肿瘤较小(直径≤4 cm)患者的总生存期(HR=3.75,P<0.0001)高于肿瘤较大(直径>4 cm)的患者。结论化疗耐药的发展加剧了胰腺癌患者预后,肿瘤大小可能是影响化疗耐药性的关键因素。Objective To explore the relationship between chemotherapy resistance and clinical characteristics in patients receiving gemcitabine adjuvant therapy after pancreatic cancer surgery,as well as its impact on patient prognosis.Methods Clinical data of 100 patients diagnosed with pancreatic cancer in Changzhou Maternal and Child Health Hospital from January 2022 to December 2023 were collected,and the correlation between chemotherapy resistance and clinical characteristics or patient prognosis was retrospectively analyzed.Results Tumor size may be a key factor affecting chemotherapy resistance(HR=3.75,P<0.0001).Patients in the chemotherapy resistance group had a poorer overall survival(HR=15.82,P<0.0001);patients with smaller tumors(diameter≤4 cm)had a higher overall survival(HR=3.75,P<0.0001)than those with larger tumors(diameter>4 cm).Conclusion The development of chemotherapy resistance exacerbates the prognosis of pancreatic cancer patients.Tumor size may be a key factor affecting chemotherapy resistance.

关 键 词：胰腺癌 吉西他滨 化疗耐药 预后 

分 类 号：R735.9[医药卫生—肿瘤]